Physician
Ukiah Adventist Hospital
Ukiah Adventist Hospital was paid $48.97M by Medicaid between Jan 2018 and Nov 2024, across 358 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 12% of everything it billed.
33Billing provider infoUKIAH ADVENTIST HOSPITAL
UKIAH, CA 95482
UKIAH, CA 95482
33aNPI1235120676assigned 11/03/2005
33bProvider typeAllergy & Immunology Physician
28Total paid$48.97M
24GClaims1,062,966
24DCodes billed358
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Allergy & Immunology Physician providers in California
Rank by total paid#1 of 68
Median peer was paid$64K
This provider vs. median763×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 156,935 | $8.89M | |
| 2019 | 167,659 | $7.68M | |
| 2020 | 136,119 | $5.17M | |
| 2021 | 146,356 | $6.43M | |
| 2022 | 153,911 | $6.96M | |
| 2023 | 170,505 | $7.67M | |
| 2024incomplete | 131,481 | $6.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 12% | 55,609 | 46,371 | $6.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 84,121 | 69,157 | $4.98M |
| 0121 | 7.2% | 1,330 | 1,272 | $3.53M | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.3% | 19,327 | 15,878 | $2.57M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 7,942 | 7,771 | $1.92M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.4% | 36,590 | 6,850 | $1.65M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 14,569 | 12,645 | $1.45M |
| 0122 | 2.9% | 760 | 752 | $1.43M | |
| 99201 | 2.2% | 6,269 | 5,218 | $1.07M | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.1% | 8,459 | 8,369 | $1.01M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 11,409 | 9,406 | $858K |
| 97139 | 1.7% | 23,233 | 4,048 | $813K |
346 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,060 | $802K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 4,433 | $708K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 15,031 | $688K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.3% | 20,057 | $647K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 8,110 | $623K |
| 97750 | 1.2% | 6,627 | $604K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.1% | 1,824 | $560K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,885 | $473K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,643 | $420K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,332 | $414K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,140 | $402K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,353 | $395K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,506 | $389K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,865 | $385K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,478 | $382K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,384 | $368K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,241 | $357K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,060 | $346K |
| J3490 | Unclassified drugs | <1% | 38,878 | $345K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 15,414 | $343K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,418 | $338K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 886 | $328K |
| 76830 | Ultrasound, transvaginal | <1% | 3,558 | $312K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,960 | $306K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,256 | $289K |
| 80053 | Comprehensive metabolic panel | <1% | 37,006 | $279K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 49,520 | $273K |
| 71045 | Radiologic examination, chest; single view | <1% | 21,756 | $254K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,745 | $248K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 740 | $247K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,759 | $237K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,114 | $210K |
| 76642 | <1% | 2,484 | $193K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 582 | $192K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 1,472 | $178K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,512 | $171K |
| 0171 | Inj, epinephrine (belcher) | <1% | 772 | $162K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,784 | $161K |
| 76801 | <1% | 1,792 | $159K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,445 | $157K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,970 | $151K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,619 | $150K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,636 | $150K |
| 72141 | <1% | 397 | $147K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,393 | $134K |
| 76770 | <1% | 1,334 | $134K | |
| 73221 | <1% | 356 | $128K | |
| 73630 | <1% | 4,518 | $124K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,118 | $124K |
| 73610 | <1% | 3,335 | $115K | |
| 93971 | <1% | 719 | $112K | |
| 73030 | <1% | 3,384 | $110K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,098 | $110K |
| 77066 | Tomosynthesis, mammo | <1% | 538 | $109K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 222 | $108K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 305 | $105K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,995 | $104K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 478 | $103K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,859 | $103K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 180 | $102K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,316 | $101K |
| 73130 | <1% | 2,870 | $99K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,290 | $97K |
| 73110 | <1% | 2,666 | $95K | |
| Z9725 | <1% | 2,007 | $86K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,881 | $86K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 448 | $86K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,674 | $85K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,382 | $84K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,014 | $84K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,510 | $83K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 385 | $79K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,591 | $79K |
| 80061 | Lipid panel | <1% | 8,377 | $75K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 360 | $75K |
| 81001 | <1% | 22,389 | $73K | |
| 73564 | <1% | 1,818 | $73K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,017 | $72K |
| 72110 | <1% | 1,060 | $71K | |
| 77065 | Tomosynthesis, mammo | <1% | 505 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,592 | $68K |
| 90715 | <1% | 1,342 | $68K | |
| 80055 | <1% | 2,104 | $67K | |
| 99070 | <1% | 4,608 | $65K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,737 | $64K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,052 | $63K |
| 76536 | <1% | 706 | $60K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,433 | $56K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,983 | $56K |
| 99205 | Prolong outpt/office vis | <1% | 601 | $54K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 548 | $54K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,632 | $52K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,161 | $51K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,210 | $51K |
| 80306 | <1% | 2,988 | $51K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 1,445 | $49K |
| 83690 | <1% | 9,011 | $46K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 136 | $46K |
| 99243 | <1% | 509 | $45K | |
| 81025 | <1% | 14,633 | $45K | |
| 87186 | <1% | 5,938 | $44K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,772 | $44K |
| 59025 | Fetal non-stress test | <1% | 1,225 | $44K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 459 | $44K |
| 94664 | <1% | 1,817 | $44K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,853 | $43K |
| 73562 | <1% | 1,306 | $42K | |
| 92015 | Determination of refractive state | <1% | 2,745 | $41K |
| 84484 | <1% | 5,170 | $41K | |
| 87077 | <1% | 6,265 | $40K | |
| 86803 | <1% | 3,880 | $39K | |
| 72020 | <1% | 1,950 | $38K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 489 | $38K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,747 | $31K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,565 | $31K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,600 | $31K |
| 92133 | <1% | 1,379 | $31K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 988 | $30K |
| 87040 | <1% | 2,922 | $29K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,968 | $29K |
| 73080 | <1% | 646 | $29K | |
| 73502 | <1% | 703 | $29K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 697 | $28K |
| 83880 | <1% | 1,059 | $26K | |
| 84439 | <1% | 4,203 | $26K | |
| 83605 | <1% | 2,948 | $25K | |
| 82728 | <1% | 2,746 | $25K | |
| 77002 | <1% | 373 | $25K | |
| 88142 | <1% | 1,370 | $24K | |
| 84466 | <1% | 2,701 | $23K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 459 | $22K |
| 81003 | <1% | 10,665 | $21K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 259 | $21K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,761 | $21K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 353 | $21K |
| 87081 | <1% | 4,369 | $21K | |
| 80143 | <1% | 1,361 | $21K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 115 | $20K |
| 99460 | <1% | 357 | $18K | |
| 80179 | <1% | 1,320 | $18K | |
| 74018 | <1% | 796 | $18K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,884 | $18K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,395 | $18K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 848 | $18K |
| 83735 | <1% | 3,629 | $18K | |
| 80076 | <1% | 3,170 | $17K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 72 | $17K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 303 | $16K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 27 | $16K |
| 85610 | <1% | 5,545 | $16K | |
| 87070 | <1% | 2,597 | $16K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,605 | $16K |
| 73140 | <1% | 539 | $15K | |
| 86140 | <1% | 4,103 | $15K | |
| 93970 | <1% | 69 | $15K | |
| 43235 | <1% | 71 | $15K | |
| 86481 | <1% | 266 | $15K | |
| 93017 | <1% | 89 | $15K | |
| 0450 | Emergency room services | <1% | 941 | $14K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,558 | $14K |
| 83540 | <1% | 3,170 | $14K | |
| 12001 | <1% | 440 | $14K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $13K |
| 76870 | <1% | 135 | $13K | |
| 97803 | <1% | 144 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,932 | $13K |
| 10060 | <1% | 318 | $13K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 126 | $12K |
| 72100 | <1% | 290 | $12K | |
| 86592 | <1% | 3,653 | $12K | |
| 71250 | <1% | 79 | $12K | |
| 70486 | <1% | 46 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,626 | $11K |
| 87507 | <1% | 27 | $11K | |
| 93248 | <1% | 410 | $11K | |
| 92083 | <1% | 516 | $11K | |
| 72170 | <1% | 404 | $10K | |
| 31575 | <1% | 111 | $10K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,409 | $10K |
| Z7502 | <1% | 266 | $10K | |
| 97802 | <1% | 98 | $10K | |
| 82746 | <1% | 958 | $10K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 37 | $9K |
| 85379 | <1% | 1,192 | $9K | |
| 93000 | <1% | 206 | $9K | |
| 87340 | <1% | 1,231 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 161 | $8K |
| 85730 | <1% | 1,950 | $8K | |
| 0258 | <1% | 1,393 | $8K | |
| 86850 | <1% | 1,642 | $8K | |
| 87581 | <1% | 222 | $8K | |
| 87486 | <1% | 222 | $8K | |
| 85652 | <1% | 3,731 | $7K | |
| 80074 | <1% | 211 | $7K | |
| 76857 | <1% | 102 | $6K | |
| 85027 | <1% | 1,407 | $6K | |
| 82948 | <1% | 2,703 | $6K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 108 | $6K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 26 | $6K |
| 83525 | <1% | 620 | $6K | |
| 87088 | <1% | 1,131 | $6K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 28 | $6K |
| 84481 | <1% | 506 | $6K | |
| 82950 | <1% | 1,798 | $6K | |
| 82962 | <1% | 2,109 | $6K | |
| 87205 | <1% | 1,919 | $6K | |
| 31231 | <1% | 71 | $5K | |
| 82570 | <1% | 1,375 | $5K | |
| 84702 | <1% | 421 | $5K | |
| 96367 | <1% | 58 | $5K | |
| 83516 | <1% | 309 | $4K | |
| 73590 | <1% | 108 | $4K | |
| 73090 | <1% | 103 | $4K | |
| 87210 | <1% | 1,279 | $4K | |
| 86901 | <1% | 1,987 | $4K | |
| 84156 | <1% | 1,555 | $4K | |
| 87147 | <1% | 1,053 | $4K | |
| 84153 | <1% | 283 | $4K | |
| 93356 | <1% | 103 | $4K | |
| 84550 | <1% | 1,196 | $4K | |
| 96417 | <1% | 45 | $4K | |
| 99499 | <1% | 220 | $4K | |
| 82565 | <1% | 1,076 | $4K | |
| 74220 | <1% | 105 | $4K | |
| 73560 | <1% | 197 | $4K | |
| 86900 | <1% | 1,796 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 489 | $3K |
| 86038 | <1% | 329 | $3K | |
| 94729 | <1% | 53 | $3K | |
| 99284 | Emergency room visit (serious) | <1% | 21 | $3K |
| 82607 | <1% | 345 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 137 | $3K |
| 93246 | <1% | 118 | $3K | |
| 92136 | <1% | 139 | $3K | |
| 94726 | <1% | 51 | $3K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 14 | $3K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 463 | $3K |
| 81002 | <1% | 1,407 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 189 | $2K |
| 82043 | <1% | 612 | $2K | |
| 82805 | <1% | 113 | $2K | |
| 92134 | <1% | 92 | $2K | |
| 71271 | <1% | 12 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 345 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 46 | $2K |
| 72040 | <1% | 40 | $2K | |
| 12011 | <1% | 45 | $2K | |
| 29125 | <1% | 129 | $2K | |
| 82550 | <1% | 389 | $2K | |
| 86762 | <1% | 160 | $2K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $2K |
| 72050 | <1% | 29 | $2K | |
| 11043 | <1% | 94 | $2K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 13 | $2K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 85 | $1K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 122 | $1K |
| 82784 | <1% | 140 | $1K | |
| 84100 | <1% | 392 | $1K | |
| 94060 | <1% | 38 | $1K | |
| 12002 | <1% | 38 | $1K | |
| 88304 | <1% | 209 | $1K | |
| 74221 | <1% | 13 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 50 | $1K |
| 83655 | <1% | 108 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 22 | $1K |
| 52000 | <1% | 13 | $1K | |
| 96415 | <1% | 18 | $1K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 186 | $979.99 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 169 | $953.56 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 55 | $926.34 |
| 99462 | <1% | 33 | $910.39 | |
| 97597 | <1% | 19 | $863.70 | |
| 85007 | <1% | 375 | $863.64 | |
| 99223 | Prolong inpt eval add15 m | <1% | 12 | $825.06 |
| 76882 | <1% | 37 | $776.27 | |
| 86701 | <1% | 124 | $746.71 | |
| 73565 | <1% | 27 | $683.43 | |
| 87075 | <1% | 98 | $670.05 | |
| 86430 | <1% | 167 | $664.63 | |
| 96368 | <1% | 16 | $646.56 | |
| 82248 | <1% | 165 | $631.96 | |
| 82951 | <1% | 71 | $619.55 | |
| 86769 | <1% | 15 | $600.00 | |
| 92650 | <1% | 12 | $593.20 | |
| 94760 | <1% | 51 | $579.31 | |
| 84403 | <1% | 28 | $574.56 | |
| 84165 | <1% | 63 | $572.85 | |
| 69210 | <1% | 14 | $571.13 | |
| 83520 | <1% | 29 | $532.48 | |
| 0250 | <1% | 1,586 | $476.49 | |
| 83883 | <1% | 20 | $442.08 | |
| 87503 | <1% | 13 | $417.89 | |
| 76514 | <1% | 44 | $392.15 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 51 | $359.38 |
| 82785 | <1% | 27 | $343.83 | |
| 83970 | <1% | 12 | $334.44 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 64 | $311.93 |
| 82247 | <1% | 83 | $294.07 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 26 | $288.51 |
| 99153 | Mod sedat endo service >5yrs | <1% | 17 | $286.03 |
| 84460 | <1% | 73 | $279.16 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 39 | $276.22 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $251.89 |
| 86160 | <1% | 15 | $249.60 | |
| 84160 | <1% | 46 | $235.06 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 17 | $216.32 |
| 0300 | <1% | 1,245 | $195.73 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 21 | $194.20 |
| 85045 | <1% | 72 | $193.83 | |
| 83721 | <1% | 27 | $171.08 | |
| 86200 | <1% | 25 | $170.40 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 12 | $169.14 |
| 86225 | <1% | 14 | $153.86 | |
| 86317 | <1% | 14 | $149.24 | |
| 87045 | <1% | 14 | $138.74 | |
| 84436 | <1% | 29 | $134.96 | |
| 86364 | <1% | 12 | $126.83 | |
| 84480 | <1% | 12 | $120.84 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17 | $120.24 |
| 83615 | <1% | 28 | $116.58 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 14 | $76.87 |
| 86308 | <1% | 14 | $50.26 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 512 | $41.03 |
| 82947 | <1% | 15 | $39.60 | |
| 84155 | <1% | 13 | $38.09 | |
| 82952 | <1% | 13 | $36.01 | |
| 0301 | <1% | 1,324 | $24.49 | |
| 85018 | <1% | 13 | $22.19 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 460 | $11.60 |
| 0305 | <1% | 1,526 | $6.14 | |
| 0310 | 0% | 104 | $0.00 | |
| 0324 | 0% | 276 | $0.00 | |
| 0410 | 0% | 261 | $0.00 | |
| 0720 | 0% | 453 | $0.00 | |
| 0721 | 0% | 611 | $0.00 | |
| 0710 | 0% | 459 | $0.00 | |
| 0307 | 0% | 548 | $0.00 | |
| 0306 | 0% | 639 | $0.00 | |
| 0370 | 0% | 670 | $0.00 | |
| 0949 | 0% | 89 | $0.00 | |
| 0730 | 0% | 180 | $0.00 | |
| 0360 | 0% | 527 | $0.00 | |
| 0460 | 0% | 404 | $0.00 | |
| 0320 | 0% | 37 | $0.00 | |
| 0302 | 0% | 39 | $0.00 | |
| 0489 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEVENS, ERIC (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Adventist Health Mendocino Coast | Fort Bragg, CA | $12.53M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.